Innovation Pharmaceuticals Inc (IPIX)

[biodoc]

Every lesion must show greater than 20% reduction. Yes, the topic has been beaten to death (guilty). Bottom line: Brilacidin looks really, really good.

On a different note, I am especially intrigued by B-OM and B-opthalmic. IMO, brilacidin for these two indications should move through trials fairly quickly and my level of confidence is very high for both indications. B-opthalmic also represents a very well defined licensing opportunity that is easily carved off from the rest of the brilacidin platform.

I've been in and around the biotech space for many years and Cellceutix is by far the best opportunity I've seen in a long, long time. Mid six figure position.